Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -94.00K | 0.00 | -377.00K | -1.66M | -1.66M | -11.00K |
EBITDA | -142.36M | -129.08M | -104.58M | -106.63M | -69.43M | -21.52M |
Net Income | -128.89M | -129.47M | -96.66M | -104.79M | -70.89M | -22.76M |
Balance Sheet | ||||||
Total Assets | 409.64M | 450.98M | 276.94M | 215.65M | 295.94M | 342.72M |
Cash, Cash Equivalents and Short-Term Investments | 392.71M | 434.09M | 261.81M | 204.42M | 287.25M | 338.55M |
Total Debt | 1.15M | 1.43M | 2.42M | 2.56M | 3.29M | 0.00 |
Total Liabilities | 26.19M | 42.02M | 23.05M | 18.10M | 11.38M | 4.58M |
Stockholders Equity | 383.45M | 408.96M | 253.90M | 197.55M | 284.57M | 338.14M |
Cash Flow | ||||||
Free Cash Flow | -124.68M | -104.51M | -83.73M | -82.43M | -52.27M | -19.92M |
Operating Cash Flow | -124.83M | -104.35M | -83.73M | -82.06M | -50.69M | -19.87M |
Investing Cash Flow | -118.47M | -93.53M | -4.85M | 91.48M | -275.44M | -56.00K |
Financing Cash Flow | 260.22M | 268.82M | 133.41M | 476.00K | 1.39M | 358.40M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $622.44M | ― | -159.34% | ― | -48.97% | 69.32% | |
52 Neutral | $283.56M | 68.60 | 2.88% | ― | ― | 61.09% | |
51 Neutral | $7.55B | 0.39 | -61.90% | 2.32% | 17.14% | 1.55% | |
51 Neutral | $447.69M | ― | -79.51% | ― | -100.00% | 10.73% | |
50 Neutral | $472.32M | ― | 3.77% | ― | ― | ― | |
46 Neutral | $299.00M | ― | -41.59% | ― | ― | 0.42% | |
41 Neutral | $266.15M | ― | -1.94% | ― | -32.07% | 98.22% |
On March 5, 2025, Olema Pharmaceuticals announced the availability of a presentation for investors, highlighting their strategic priorities and clinical pipeline advancements. The company is actively accruing patients for pivotal Phase 3 trials of palazestrant, aiming for a potential commercial launch in 2027, and has announced a new collaboration with Novartis. These developments could significantly impact Olema’s market positioning and offer promising treatment options for breast cancer.